There are no adequate and well-controlled studies with epoetin alfa in pregnant women. ESA should be administered during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the foetus. In pregnant or lactating surgical patients participating in an autologous blood predonation programme, the use of ESA is not recommended. It is not known whether epoetin alfa (rch) is excreted in breast milk.